study to assess the concentration of Avibactam and Ceftazidime in epithelial lining fluid and plasma

Study identifier:D4280C00009

ClinicalTrials.gov identifier:NCT01395420

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

A Phase I Open-Label, 2-Part, 3-Cohort, Single-Centre Study to Assess the Concentration of Avibactam and Ceftazidime in Epithelial Lining Fluid (ELF) and Plasma Using at Least Two Different Dosing Regimens in Healthy Volunteers

Medical condition

Healthy

Phase

Phase 1

Healthy volunteers

Yes

Study drug

CAZ104

Sex

All

Actual Enrollment

45

Study type

Interventional

Age

18 Years - 50 Years

Date

Study Start Date: 01 Aug 2011
Primary Completion Date: 01 Jul 2012
Study Completion Date: 01 Jul 2012

Study design

Allocation: Non-randomized
Endpoint Classification: Safety Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Basic Science

Verification:

Verified 01 Apr 2016 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

-

Inclusion and exclusion criteria